A pooled analysis from six Phase 3 studies investigating the efficacy of a JAK1/JAK3 inhibitor in patients with RA revealed no differences in efficacy outcomes across BMI categories (BMI < 25, 25 to < 30, and ≥ 30 kg/m2). This evidence concerns the gene JAK3 and rheumatoid arthritis.